A Case Report of Ketamine-induced Hypoglycemia in Treatment Resistance Depression
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Ketamine therapy can reduce the risk of suicide and depression in the treatment resistant patient. Adverse effects of ketamine infusion include blurred vision, nausea and vomiting, hepatotoxicity, headache, and cystitis. However, the effect of ketamine infusion on blood glucose remains unclear. This report describes several episodes of hypoglycemia in a 36-year-old man with type 1 diabetes mellitus after ketamine infusion for treatment-resistance depression. He has been receiving subcutaneous insulin injection and denied any severe hypoglycemia events in the prior 20 years. He had unsuccessful treatment for depression. His depressive conditions were subsequently improved due to ketamine therapy, however, he had recurrent hypoglycemia episodes. Clinicians should be aware of this potential adverse effect on initiating ketamine infusion with patients who had type 1 diabetes.
Abstract
Ketamine therapy can reduce the risk of suicide and depression in the treatment resistant patient. Adverse effects of ketamine infusion include blurred vision, nausea and vomiting, hepatotoxicity, headache, and cystitis. However, the effect of ketamine infusion on blood glucose remains unclear. This report describes several episodes of hypoglycemia in a 36-year-old man with type 1 diabetes mellitus after ketamine infusion for treatment-resistance depression. He has been receiving subcutaneous insulin injection and denied any severe hypoglycemia events in the prior 20 years. He had unsuccessful treatment for depression. His depressive conditions were subsequently improved due to ketamine therapy, however, he had recurrent hypoglycemia episodes. Clinicians should be aware of this potential adverse effect on initiating ketamine infusion with patients who had type 1 diabetes.
참고문헌 (8)
- Cohen SP, "Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists", Reg Anesth Pain Med, 43, pp.521~546 (2018)
- American Diabetes Association Professional Practice Committee, "6. Glycemic targets : Standards of medical care in diabetes-2022", Diabetes Care, 45(Suppl 1), pp.S83~S96 (2022)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30, pp.239~245 (1981)
- Sharif SI, "Effect of intravenous ketamine administration on blood glucose levels in conscious rabbits", Am J Pharmacol Toxicol, 4, pp.38~45 (2009)
- Chen H, "Diabetes alters the blood glucose response to ketamine in streptozotocin-diabetic rats", Int J Clin Exp Med, 8, pp.11347~11351 (2015)
- Melanson B, "Impact of impaired glucose metabolism on responses to a psychophysical stressor : Modulation by ketamine", Psychopharmacology(Berl), 238, pp.1005~1015 (2021)
- Boku S, "Neural basis of major depressive disorder : Beyond monoamine hypothesis", Psychiatry Clin Neurosci, 72, pp.3~12 (2018)
- Inouye K, "Mechanisms of impaired hypothalamic-pituitary-adrenal(HPA)function in diabetes : Reduced counterregulatory responsiveness to hypoglycaemia", Diabetes Nutr Metab, 15, pp.348~355 (2002)